Literature DB >> 18718888

Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients.

E Boveri1, L Arcaini, M Merli, F Passamonti, S Rizzi, L Vanelli, E Rumi, S Rattotti, M Lucioni, C Picone, A Castello, C Pascutto, U Magrini, M Lazzarino, M Paulli.   

Abstract

BACKGROUND: Among marginal zone lymphomas (MZLs), bone marrow (BM) involvement features are well established in the splenic marginal zone lymphoma (SMZL); few data are available for extranodal marginal zone lymphoma (EMZL) and nodal marginal zone lymphoma (NMZL). PATIENTS AND METHODS: Incidence and patterns of histologic BM involvement are studied in 120 MZL patients (48 SMZL, 59 EMZL, 13 NMZL) at onset and during follow-up; relationships between clinical features, BM histology and flow cytometry (FC) are analyzed.
RESULTS: At diagnosis, BM involvement occurs in 90% SMZL, 22% EMZL and 54% NMZL (P<0.0001); at reevaluation, incidence raises to 96% in SMZL and 34% in EMZL. Concordance between histology and FC is found in 87% of cases; most discordant cases have positive histology but negative FC. SMZL and EMZL show a nodular BM infiltration; the interstitial pattern is frequent in NMZL (P<0.0001); sinusoidal localization is typical of SMZL, frequent in NMZL and occasional in EMZL (P=0.0001). Stage, leukemic disease, B symptoms, more than one extranodal involved site, splenomegaly, elevated beta2-microglobulin, serum monoclonal component, International Prognostic Index (IPI) and age-adjusted IPI are directly related to BM infiltration.
CONCLUSIONS: The different prevalence of BM involvement in MZL subtypes reflects their heterogeneous dissemination modalities; histology seems more sensible than FC to detect BM infiltration; development of BM involvement during follow-up is typical of EMZL.

Entities:  

Mesh:

Year:  2008        PMID: 18718888     DOI: 10.1093/annonc/mdn563

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  Splenic marginal zone lymphoma: hydra with many heads?

Authors:  Luca Arcaini; Marco Paulli
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

Review 2.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

3.  Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.

Authors:  Rajko Milosevic; Milena Todorovic; Bela Balint; Miodrag Jevtic; Miodrag Krstic; Elizabeta Ristanovic; Nebojsa Antonijevic; Mirjana Pavlovic; Maja Perunicic; Milan Petrovic; Biljana Mihaljevic
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

4.  First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Authors:  Roberto Castelli; Luigi Bergamaschini; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2017-12-29       Impact factor: 3.064

Review 5.  Prognostic factors in low-grade non-Hodgkin lymphomas.

Authors:  Massimo Federico; Stefano Molica; Monica Bellei; Stefano Luminari
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

Review 6.  Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.

Authors:  Michiel van den Brand; J Han J M van Krieken
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

Review 7.  Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.

Authors:  Nathan M Denlinger; Narendranath Epperla; Basem M William
Journal:  Cancer Manag Res       Date:  2018-03-27       Impact factor: 3.989

Review 8.  Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature.

Authors:  Wataru Kitamura; Noboru Asada; Tetsuya Tabata; Rei Shibata; Tatsuya Nishi; Yuka Kato; Hiroki Takasuka; Hideaki Fujiwara; Daisuke Ennishi; Hisakazu Nishimori; Nobuharu Fujii; Ken-Ichi Matsuoka; Katsuyuki Kiura; Tadashi Yoshino; Yoshinobu Maeda
Journal:  J Clin Exp Hematop       Date:  2021-11-26

9.  Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma.

Authors:  Enrico Munari; Marianna Rinaldi; Achille Ambrosetti; Massimiliano Bonifacio; Angela Bonalumi; Marco Chilosi; Alberto Zamò
Journal:  Virchows Arch       Date:  2012-10-14       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.